Monday, 20 May 2019

You are here

Combination or Monotherapy Tocilizumab in Rheumatoid Arthritis

Several rheumatoid arthritis studies have shown that tocilizumab (TCZ) may be as effective as monotherapy when compared to combination therapy (methotrexate plus TCZ), including the ACT-RAY, ACT-SURE and FUNCTION clinical trials.

But it is still unclear if it is prudent to initiate TCZ treatment in RA as monotherapy or in combination with a DMARD or MTX.  The SURPRISE study is a 2-year, randomized trial of 223 active RA patients with an incomplete response to MTX who either add TCZ to MTX or switch from MTX TCZ monotherapy.  

At week 24, DAS28 (and CDAI, SDAI) remission rates were higher in those with combination TCZ (70 vs 55%) compared to TCZ monotherapy.  The ACR20/50/70 the differences between the two treatment groups were not significant, although there was a trend towards superiority of TCZ added to MTX to TCZ switched from MTX. X-ray benefits were also greater in those on combination MTX and TCZ, with X-ray progression being worse in those on TCZ monotherapy (15% vs 7%).

Overall, in those RA patients with an inadequate response to methotrexate, tocilizumab added to methotrexate more rapidly suppressed inflammation than tocilizumab switched from methotrexate, leading to superior clinical efficacy and prevention of joint destruction.

The author has received research/grant financial support on this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

FDA Final Guidance on Interchangeability with Biosimilars

The FDA has published an industry guidance document to define interchangeability as regards to biosimilar use in the United States under section 351(k) of the Public Health Service Act (PHS Act) (42 U.S.C. 262(k)). 

Ustekinumab Effective in Behcet's Disease

A small prospective study has shown that ustekinumab is safe and effective in Behçet's disease (BD) with recurrent oral ulcers (OU).

Polypharmacy Blunts Responses and Ups the Safety Risks

A study from the British Society for Rheumatology Biologics Register (BSRBR-RA) demonstrates that polypharmacy is a predictor of lower treatment responses and more serious adverse events (SAEs) in rheumatoid arthritis (RA) patients.

RheumNowLive On Demand: Development & Use of JAK Inhibitors - Dr. John O'Shea

A clip from RheumNow Live On Demand. You can access the full library of content from the meeting.

For RA With COPD, Abatacept is Safe

Patients with rheumatoid arthritis (RA) who also had chronic obstructive pulmonary disease (COPD) had no increased risk of serious respiratory complications when treated with abatacept (Orencia), a large claims-based analysis found.